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HANDLING MISSING VALUES IN COST-EFFECTIVENESS
ANALYSES THAT USE DATA FROM CLUSTER RANDOMISED
TRIALS.
KARLA DI´AZ-ORDAZ, MICHAEL G. KENWARD, AND RICHARD GRIEVE
Abstract. Public policy-makers use cost-effectiveness analyses (CEA) to de-
cide which health and social care interventions to provide. Appropriate meth-
ods have not been developed for handling missing data in complex settings,
such as for CEA that use data from cluster randomised trials (CRTs). We
present a multilevel multiple imputation (MI) approach that recognises when
missing data have a hierarchical structure, and is compatible with the bivariate
multilevel models used to report cost-effectiveness. We contrast the multilevel
MI approach with single-level MI and complete case analysis, in a CEA along-
side a CRT. The paper highlights the importance of adopting a principled
approach to handling missing values in settings with complex data structures.
1. Introduction
Public policy-makers use cost-effectiveness analyses (CEA) in deciding which
health and social care interventions to prioritise (NICE, 2008; CADTH, 2006;
PBCA, 2008; IQWIG, 2009). CEA exploit evidence from randomised studies, and
if they adopt appropriate statistical methods, can provide accurate assessments of
which interventions are most worthwhile (Gold et al., 1996; O’Hagan et al., 2001;
Willan and Briggs, 2006; Glick et al., 2007; Gray et al., 2010). CEA raise major
challenges for the analytical approach as the data tend to have complex struc-
tures, with correlated cost and effectiveness endpoints (Willan et al., 2003; Willan,
2006), hierarchical data (Manca et al., 2005; Pinto et al., 2005), and costs with
right-skewed distributions (Manning, 2006; Jones et al., 2011). Most CEA that use
individual-level data have observations with incomplete information (Noble et al.,
2012). Statistical methods have not been developed that can simultaneously ad-
dress all these issues. Hence studies may fail to provide the unbiased, precise
cost-effectiveness estimates that decision-makers require.
This paper is motivated by CEA that use data from cluster randomised trials
(CRTs), but the approach we propose addresses three issues of general relevance.
The first issue is raised by the bivariate nature of the outcomes, which implies
the need for joint modelling. Here, one endpoint is highly skewed, but inferences
about means are still required on the original scales of measurement. The second
issue is that randomisation is at the cluster level, which implies that the data are
hierarchical. The third issue, and the focus of this paper, is the presence of missing
data.
Key words and phrases. missing data, multiple imputation, bivariate models, cost-
effectiveness.
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Approaches have been proposed for jointly modelling costs and health outcomes
while acknowledging that individual costs tend to have right-skewed distributions
(Thompson and Nixon, 2005). There is a large literature on methods for handling
clustered data, see for example Hayes and Moulton (2009), Eldridge (2012), Aerts
et al. (2002), Goldstein (2003). Methods for CEA alongside CRT include: a ‘two-
stage’ non-parametric bootstrap procedure (Flynn and Peters, 2005; Bachmann
et al., 2007); bivariate Generalised Estimating Equations with robust standard er-
rors (Gomes et al., 2012), and bivariate multilevel models (MLMs). Amongst the
MLMs proposed are bivariate Normal models estimated by maximum likelihood
(Gomes et al., 2012), or with Bayesian Markov-Chain Monte Carlo (MCMC) meth-
ods (Grieve et al., 2010; Bachmann et al., 2007).
An outstanding issue is handling missing data in CEA with complex structures.
For example, in a CRT, the prevalence of missing endpoint data may differ accord-
ing to individual and cluster-level characteristics (e.g cluster size). CEA methods
guidance recommends multiple imputation (MI) (Blough et al., 2009; Briggs et al.,
2003; Ramsey et al., 2005), but most published CEA still use complete case analysis
(Noble et al., 2012). While MI approaches have been proposed for handling missing
data with a clustered structure (Carpenter and Goldstein, 2004; Schafer and Yucel,
2002), no previous study has developed methods for handling missing hierarchical
data in complex settings, such as those seen in CEA that use cluster trials.
The aim of this paper is to develop and illustrate an overall approach to analysing
studies which have: bivariate outcomes with one highly skewed endpoint, a clustered
structure and missing data. We do this using MI within a frequentist paradigm.
At the same time, we explore the implications of failing to acknowledge relevant
features of the setup in the handling of the missing data, in particular the potential
consequences of ignoring clustering in the imputation step, and departures from
Normality. We also compare the results we obtain with those from an analysis
restricted to those individuals with complete data.
In Section 2, we introduce our case study which is a typical CEA that uses
CRT data. In Section 3, we develop a simple modelling framework for a clustered
bivariate pair of outcomes, one of which has a potentially non-Normal distribution.
Section 4 considers in some detail the handling of missing data in this setup, and
explores the use of multilevel MI for this problem. In Section 5, we compare the
results obtained from a range of alternative strategies. We close with a discussion
in Section 6.
2. Motivating example: The PoNDER study
The PoNDER study (psychological interventions for post-natal depression trial
and economic evaluation) was a CRT evaluating an intervention for preventing
postnatal depression, (Morrell et al., 2009). It included 2659 patients who attended
101 primary care providers in the UK (general practices). Clusters were randomly
allocated to provide either usual care (control) or an intervention delivered by
a health visitor (treatment). The intervention comprised health visitor training
to identify and manage patients with postnatal depression. As is common, the
PoNDER CRT had an unbalanced design; the number of patients per cluster varied
widely (from 1 to 101 in the control group and from 1 to 81 in the treatment group).
Patients were followed up for 18 months with costs (£ sterling) and health-
related quality of life (HRQoL) recorded at six monthly intervals. This paper
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Table 1. Description of missing data in the PoNDER case study,
by treatment group.
Control group Intervention group
(Total n=911) (Total n=1730)
Outcome variables type symbol Missing n % Missing n %
Cost continuous cij 402 41.1 460 26.6
QALY continuous qij 39 4.3 59 3.4
Baseline variables
Edinburgh Postnatal
Depression Scale continuous epdsij 0 0 0 0
Ethnicity binary ethij 0 0 0 0
Economic status binary ecoij 0 0 0 0
Age continuous ageij 1 0.1 0 0
English as first language binary engij 0 0 0 0
Living alone binary alij 9 1.0 7 0.4
Partner’s economic status ordinal peij 7 0.8 10 0.6
Benefits binary bij 19 2.1 38 2.2
History of depression binary dij 5 0.5 6 0.3
Any major life events binary lij 8 0.9 9 0.5
Relationship with baby ordinal rbij 12 1.3 20 1.2
considers costs and HRQoL reported at six months. These HRQoL data were
used to adjust life years and present quality-adjusted life years (QALYs) over six
months. Intra-cluster correlation coefficients (ICCs) were moderate for QALYs
(ICCq=0.04), but high for costs (ICCc=0.17). While QALYs were approximately
Normally distributed, costs were moderately skewed.
Baseline measurements were collected from mothers at six weeks post-natally,
for variables anticipated to be prognostic for either cost or effectiveness endpoints.
Table 1 reports the percentage of observations with missing data, by treatment
group. For each baseline variable, less than 2.5% of participants had missing data,
but a relatively high proportion of individuals had missing data for the cost end-
point; 31 clusters were without any observed cost data (15 in the control arm,
including one cluster that withdrew from the study).
The CEA presents incremental QALYs and costs as the differences in means,
between the treatment and control groups (Morrell et al. 2009b). Cost-effectiveness
is then reported as incremental net monetary benefits (or INB, see equation (6) for
definition).
To simplify the exposition, we restrict our analyses to those individuals with
positive costs, by excluding 18 observations with zero costs (15 in the treatment
group). See Section 6 for further discussion.
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3. Substantive model
Let Cij and Qij be the cost and QALY outcomes respectively from the jth
patient in cluster i of a two-armed CEA alongside a CRT. We assume that the
observations from different clusters are independent.
We are principally concerned with estimating the linear additive effect of treat-
ment on mean costs and health outcomes, with no additional covariates. Because
of the simplicity of our setup, we are able to model the data from the two treatment
groups entirely separately, and then make the comparison. So, in the following, we
show the development for one treatment group; exactly the same arguments apply
to the other.
First, we introduce bivariate Normal latent variables {ui, wi} to represent pos-
sible cluster effects for cost and QALYs respectively, with
(1)
(
ui
wi
)
∼ N
[(
0
0
)
,
(
σ2u ρσuσw
ρσuσw σ
2
w
)]
,
where σ2u, σ
2
w, and ρ are the variances and correlation of the two latent variables
respectively.
We now build the bivariate substantive model on the expectations of the two
outcomes, Cij and Qij , defined conditionally on the two cluster effects, first for
cost:
(2) µC = E[Cij | ui, wi] = β1 + ui
with β1 the mean appropriate for the first treatment group, and then for QALYs,
conditional on the costs and cluster effects
(3) µQ = E[Qij | cij , ui, wi] = γ1 + αcij + wi,
with γ1 the intercept for Qij for the first treatment group, and α the corresponding
regression coefficient for the costs.
We now introduce distributions for Cij and Qij , conditional on the cluster effects.
It is assumed that the conditional distribution of Qij given Cij is Normal, with
variance σ2q . We consider three possible distributions for Cij : Normal, Lognormal
and Gamma. Other distributions could of course also be considered if thought
appropriate. The choice of the Normal is straightforward, the mean is given by
(2), with some variance σ2c say. The Gamma alternative is introduced with a
parameterisation that implies that the coefficient of variation,
√
η say, is constant
across clusters; in contrast to the Normal which implies constant variance. For
µC , the conditional mean as given in (2), the chosen Gamma density can then be
written
(4) fC(c) =
1
Γ(η)
(
η
µC
)η
xη−1 exp(−ηx/µC).
To maintain comparability with the Gamma distribution, we introduce the Lognor-
mal with a somewhat unusual parameterisation, in which the coefficient of variation
is again constant across clusters. This gives
(5) fC(c) =
1
c
√
2pi log(1 + η)
exp
{
− (log c− µC)
2
2 log(1 + η)
}
.
We assume that, conditional on the cluster effects, (Cij , Qij) is independent of
(Cij′ , Qij′ ) for j 6= j′, and so the required joint density, still conditional on the
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cluster effects, can be obtained from the product of the densities for [Cij | ui, wi]
and [Qij | Cij , ui, wi].
Finally, to obtain the marginal likelihood for the data for one treatment group,
it is then necessary to combine this joint density over all relevant patients, and
then integrate over the distribution of the cluster effects. This needs to be done
numerically. There are several approaches for this, here we have used adaptive
Gaussian quadrature as implemented in SAS PROC NLMIXED. We provide sample
code for this in Appendix A.
Using conventional likelihood procedures we can then obtain estimated means
for cost and QALYs (µˆC,k and µˆQ,k say) for treatment groups k = 1, 2 respectively,
together with their estimated variances and covariances. Note that the separate
modelling steps for the two treatment groups implies that estimates are independent
between groups. The increments between the two groups are then estimated as
δˆC = µˆC,2 − µˆC,1 and δˆQ = µˆQ,2 − µˆQ,1.
The relative cost-effectiveness of treatment 2 against treatment 1 can be sum-
marised by the INB defined as
(6) INB(λ) = λδQ − δC
for λ, a given threshold willingness to pay for a unit of health gain. Its standard
error can be calculated from the estimated variances and covariances of δˆC and δˆQ
in the usual way.
4. Missing Data
4.1. Handling the missing data. It is well known that missing data can be the
source of selection bias, and we are rarely able to construct analyses in which we can
be confident that such bias has been eliminated. Rather, we use what information
is available both in the data and the substantive setting in an attempt to reduce
potential bias. Following this, carefully targeted sensitivity analysis can play an
valuable role. There are many ways in which analyses can attempt to deal with
missing data, and in which sensitivity analysis can be constructed, see for example
Little and Rubin (2002) and Molenberghs and Kenward (2007).
One important source of information that can be used to potentially reduce
bias is contained in observed variables that are associated both with the outcome
and with the missing value process itself. If these variables are not part of the
substantive model, they are termed auxiliary variables in the missing value context.
There are several potential auxiliary variables in the current setting, and we
will use an approach which can incorporate them. To explain the intended role of
these variables we need to introduce some definitions due to Rubin (1976). We use
these in a fairly loose way here, more formal expositions can be found in the books
mentioned above, and in the references given there. One important distinction
here from Rubin’s original definitions, is our use of these terms in a frequentist
framework, which implies rather stronger conditions than Rubin’s likelihood based
definitions.
Let Yij = {Yij1, Yij2} = {Cij , Qij} be the pair of observations from subject
(i, j) and define the random variable Rijl to take the value 1 if Yijl is observed
and 0 if missing. We say that the missing data are Missing Completely at Random
(MCAR) if Rijl and Yijl are independent. By contrast, the data are Missing at
Random (MAR) if there are observed variables, contained in V say, such that Rijl
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and Yijl are conditionally independent given V. It can be seen that MCAR implies
MAR. We can reject the MCAR assumption in favour of MAR if we see associations
between observed variables and Rijl, which is of course completely observed.
If neither MCAR nor MAR hold, we say that the missing data are Missing Not
at Random (MNAR). It usually impossible to rule out MNAR in practice from
the data at hand, because this depends critically on the existence of associations
between unobserved variables and the Rijl, which the observed data cannot exclude.
It is this dependence between Rijl and Yijl that is the potential source of bias.
It is therefore usually sensible to try at least to reduce this dependence by iden-
tifying potential auxiliary variables from among those observed, and this will form
the first step in handling the missing data. This will be done separately for the two
outcomes, because it is entirely plausible that very different missing value mech-
anisms will operate with the two outcomes. We make the simplifying assumption
that our auxiliary variables are completely observed. This is not strictly necessary,
and in principle the approach used here can be extended to the situation when they
are not, but for our present purposes the restriction to complete variables permits
a simpler exposition.
4.2. Multiple Imputation. Having identified potential auxiliary variables, it is
necessary to incorporate them into the analysis. If these variables were part of
the substantive model, we could simply include them and so condition on them,
and in this way reduce or remove the unwanted dependence between Rijl and Yijl.
But as auxiliary variables, they are not in the substantive model, so this route is
not available to us. Alternatively, we could construct an overall joint model in
which these auxiliary variables are included as additional outcome variables. In the
current setting this is awkward, although not infeasible, because of the clustered
structure.
We instead choose to use multiple imputation (Rubin, 1978; Kenward and Car-
penter, 2007). This has the advantage of retaining the original substantive model,
adding to this an imputation model. This is essentially determined by the condi-
tional distribution of the missing data given the observed data, which we allow to
differ between outcomes and treatment arms.
In the present setting, in which we are only considering missing data in the out-
come, the conditional model follows from the substantive model. We note the role
of the clustering in this: the observations from one cluster are mutually dependent,
and so the conditional distribution of a missing value involves all the other observed
values in the same cluster. To this basic model (or models) we add the auxiliary
variables, again acknowledging the clustered structure.
Given the substantive and imputation models, conventional MI procedures can
be followed. These are set out in detail in many references, including Little and
Rubin (2002) and Molenberghs and Kenward (2007). The overall MI procedure is
as follows.
(1) The imputation model is fitted to the observed data and Bayesian draws are
taken from the posterior of the model parameters.
(2) The missing data are imputed from the imputation model, using the parameters
drawn in step (1).
(3) The substantive model is fitted (here using maximum likelihood) to the data set
HANDLING MISSING VALUES IN COST-EFFECTIVENESS ANALYSES OF CRT 7
that has been completed using the imputations from step (2), producing parameter
estimates and their estimated covariance matrix.
(4) Steps (1)-(3) are repeated a fixed number, K say, of times.
(5) The K sets of parameter and covariance estimates from step (3) are then com-
bined using Rubin’s formulae (Rubin, 1987) to produce a single MI estimate of the
substantive model parameters and associated covariance matrix.
Under the MAR assumption, this will produce consistent estimators and in the
absence of auxiliary variables, is asymptotically (as K increases) equivalent to max-
imum likelihood.
For the current analysis, the whole MI procedure has been done separately for
the two treatment groups. To carry this out, we do need the facilities to make
the required Bayesian draws from the imputation model, which is bivariate and
includes a cluster random effect. One route for this is the MLwiN procedures
developed by Carpenter and Goldstein (2004). This is restricted however to the
multivariate Normal distribution, and the imputation step has been undertaken
on the log of the costs, transforming back to the original scale in step (3) above.
The approximation implied under the Lognormal and Gamma substantive models
is unlikely to be critical. The more flexible multilevel imputation procedure of
Carpenter et al. (2011) might be considered for future work, or a bespoke sampler
developed for the specific bivariate models used here.
4.3. Specifying the imputation model for the PoNDER case study. To
investigate the associations of observed variables with the Rijl, it is natural to use
logistic regression, in this example with and without random cluster effects. This
has been done separately here for cost (l = 1) and QALYs (l = 2) and also for each
treatment group (k = 1, 2).
In addition to the patient-level covariates described, we added the cluster-level
variable cluster size, ni, defined as the number of participants randomised in each
cluster. Previous studies suggest that cluster size may be associated with costs
or health outcomes (Campbell et al., 2000; Omar and Thompson, 2000; Neuhaus
and McCulloch, 2011). We also consider that the number of participants recruited
in each cluster may be associated with missingness. In PoNDER, because clinical
protocols were less restrictive in the control than treatment group, it was anticipated
that any relationship between the cluster size and the endpoints would be stronger
in the control group.
In the control group, before allowing for clustering, ethnicity, economic status
and cluster size were associated with missing costs, but after including a random
effect to allow for clustering no covariates were associated with missing costs. Clus-
ter size and epds seem to be associated with unobserved QALYs. In addition, epds
and cluster size (ni) are associated with costs and economic status, ethnicity and
epds are associated with QALYs. In the treatment group, cluster size was seen to
be associated with missing cost at the individual level, while adjusting for clustering
resulted in economic status being predictive of missing costs. Only age is predictive
of QALYs missingness, both ignoring and accounting for clustering. In addition,
epds is associated with the value of both cost and QALYs.
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Table 2. Single-level (ignoring clustering) and multilevel (ac-
counting for clustering) imputation models used for the cost and
QALY endpoints in the PoNDER case study. Models that included
a cluster-level auxiliary variable are indicated by -C.
Type Model Control Group Intervention Group
Single level SL epdsij + ecoij + ethij epdsij + ecoij + ageij
SL-C epdsij + ecoij + ethij + ni epdsij + ecoij + ageij + ni
Multilevel ML epdsij + ecoij + ethij epdsij + ecoij + ageij
ML-C epdsij + ecoij + ethij + ni epdsij + ecoij + ageij + ni
The MI algorithm implemented here assumes all variables included in the model
are multivariate Normally distributed. We exploit this by choosing the same impu-
tation models for both outcomes, adding all auxiliary variables which seem associ-
ated with either endpoint and their missingness, and modelling the two outcomes
simultaneously. The imputation models chosen are summarised in Table 2.
5. Multiple imputation estimates for the example data set
The imputation models that ignore clustering (SL, SL-C) were implemented with
the ice command in STATA (by chained equations), while the multilevel imputation
models (ML, ML-C) used multivariate Normal MCMC algorithms implemented in
MLwiN mi macros.
For each imputation model in Table 2, we obtained five imputed datasets. Figure
1 highlights the impact that accounting for clustering in the MI model can have
on the distributions of “imputed” values. It shows imputed cost data for the six
clusters in the control arm with the highest number of observations with missing
cost data. The Figure contrasts data imputed after applying the single-level im-
putation models versus the multilevel imputation which included cluster size as an
auxiliary variable. The cost distribution appears somewhat less clustered after the
single-level imputation than after multilevel imputation.
The five multiply imputed datasets were each analysed with the three substan-
tive models defined in Section 3, i.e. random cluster effects models with bivariate
Normal (N-N), Lognormal-Normal (L-N) and Gamma-Normal (G-N) distributions.
Table 3 reports the MI estimates for mean cost and QALYs by treatment arm, and
for comparison also includes estimates from complete cases (CC).
Table 3 shows that, as anticipated, the standard errors for both endpoints are
larger for the control than for the treatment group. It is also clear that ignoring
the hierarchical structure of the data in the imputation model results in different
point estimates for mean cost, especially in the control arm. For all approaches,
the estimated correlations between cost and QALYs are small.
We use the estimates from Table 3 to obtain incremental costs, QALYs and INBs
for a willingness to pay, λ, of £20000 per QALY. These are reported in Table 4.
Table 4 shows that the estimates of incremental cost, incremental QALYs and
INB are relatively insensitive to the choice of cost distribution. In fact, for the
incremental QALYs, where there is little missing data and the ICCs are low, the
estimates and their standard errors are virtually identical following each missing
data approach.
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Figure 1. Difference in the “spread” of imputed data, depend-
ing on whether the imputation model ignored or accounted for
clustering (Model SL versus Model ML-C). The Figure shows the
distribution of costs in the six control clusters with the highest
number of missing values in the original dataset.
However, inferences about the estimated incremental costs and the INBs differ
depending on the approach for handling missing data. Firstly, complete case es-
timates are likely to be biased, as the missing mechanism is probably not MCAR
and the substantive model is not adjusting for any covariates. Single-level MI ap-
proaches produce smaller standard errors than those obtained with multilevel MI
and CC. This is because cost has a large ICC and we are looking at a between-
cluster estimator. As a consequence, there is an increased risk of type I error,
regardless of the choice of cost distribution used for the substantive model.
Moreover, ignoring informative cluster size in the multilevel imputation model
increases the magnitude of the estimated standard errors. This cluster-level covari-
ate (cluster size) is associated with cost and with cost missingness, and so excluding
it from the imputation model reduces the precision of the estimate, as information
is lost. By contrast, including cluster size in the single-level imputation model re-
sults in point estimates for the incremental cost which are similar to those following
multilevel MI, although estimates for the standard errors are still smaller than the
corresponding multilevel MI estimates.
Figure 2 shows the INB (with 95% CI) at alternative thresholds of willingness
to pay for a QALY gained. With the single-level MI, the INB and 95% CI are pos-
itive throughout, indicating that the treatment is cost-effective. For the multilevel
MI that acknowledges informative cluster size, the 95% CIs around the INB are
wider and include zero at realistic thresholds for a QALY gained. While for both
approaches, the INB remains positive throughout, the single level MI approach ap-
pears to overstate both the absolute level of the INB, and the precision surrounding
the estimate.
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Table 3. Mean (SE) costs (in £ sterling) and QALYs, and es-
timated correlations between the two endpoints. Estimates are
according to choice of approach for handling missing data, and for
alternative bivariate substantive models.
Missing data approach Control Group Intervention Group
Model Estimates N-N L-N G-N N-N L-N G-N
CC Mean cost 273.3 286.6 277.2 256.8 258.5 254.6
(SE) (25.3) (23.0) (24.8) (11.7) (11.6) (10.7)
Mean QALYs 0.027 0.027 0.027 0.030 0.030 0.030
(SE) (0.0014) (0.0014) (0.0014) (0.0008) (0.0008) (0.0008)
corr(c,q) −0.03 −0.03 −0.04 −0.04 −0.04 −0.04
SL Mean cost 295.0 299.1 295.00 251.4 253.1 251.3
(SE) (16.8) (16.9) (19.1) (9.9) (9.5) (9.1)
Mean QALYs 0.027 0.027 0.027 0.030 0.030 0.030
(SE) (0.0011) (0.0011) (0.0011) (0.0007) (0.0007) (0.0007)
corr(c,q) 0.00 −0.09 −0.06 −0.09 −0.08 −0.06
SL-C Mean cost 268.1 275.5 270.4 257.2 257.5 255.4
(SE) (18.8) (16.9) (18.1) (9.1) (9.2) (8.8)
Mean QALYs 0.026 0.026 0.026 0.030 0.030 0.030
(SE) (0.0011) (0.0011) (0.0011) (0.0007) (0.0007) (0.0007)
corr(c,q) 0.01 0.05 0.001 −0.06 −0.08 −0.04
ML Mean cost 264.6 265.0 262.5 256.9 257.9 255.1
(SE) (31.6) (25.8) (29.4) (12.8) (12.9) (12.1)
Mean QALYs 0.026 0.026 0.026 0.030 0.030 0.030
(SE) (0.0011) (0.0011) (0.0011) (0.0007) (0.0007) (0.0007)
corr(c,q) 0.06 0.03 0.04 −0.07 −0.07 −0.06
ML-C Mean cost 270.0 280.6 275.0 262.1 262.5 259.5
(SE) (21.0) (23.4) (23.5) (14.0) (12.2) (12.1)
Mean QALYs 0.026 0.026 0.026 0.030 0.030 0.030
(SE) (0.0011) (0.0011) (0.0011) (0.0007) (0.0007) (0.0007)
corr(c,q) −0.09 −0.09 −0.08 0.01 0.00 0.04
Hence, in the PoNDER case study, once a more appropriate approach is taken
to handling the missing data, it is less certain that the intervention is cost-effective.
6. Discussion
This paper provides a principled approach to handling missing data with complex
structures, exemplified by CEA that use data from CRTs. The proposed approach
follows the general principle that the imputation model should reflect the structure
of the analytical model. In the context of cluster trials, just as the substantive
model can account for clustering with a MLM, so must the imputation model.
Moreover, because the analytical models typically used in CEA estimate the linear
additive effects of treatment on mean costs and health outcomes without covariate
adjustment, MI has particular appeal in this setting. By separating the imputation
and substantive models, information on those auxiliary variables, such as baseline
patient characteristics, associated with missingness and the endpoints of interest
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Table 4. Estimated incremental cost (in £ sterling), QALYS and
INBs at a threshold of £20000 per QALY. Estimates are according
to choice of approach for handling missing data for alternative
bivariate substantive models
Estimates (SE) Model N-N L-N G-N
Incremental cost CC −16.5 (27.9) −28.1 (25.8) −22.5 (27.00)
δc SL −43.6 (19.5) −46.0 (19.4) −43.7 (21.2)
SL-C −10.9 (20.9) −18.0 (19.2) −15.0 (20.1)
ML −7.7 (34.1) −7.1 (28.8) −7.4 (31.8)
ML-C −7.9 (25.2) −18.1 (26.4) −15.5 (26.4)
Incremental QALYs CC 0.003 (0.002) 0.003 (0.002) 0.003 (0.002)
δq SL 0.004 (0.001) 0.004 (0.001) 0.004 (0.001)
SL-C 0.004 (0.001) 0.004 (0.001) 0.004 (0.001)
ML 0.004 (0.001) 0.004 (0.001) 0.004 (0.001)
ML-C 0.004 (0.001) 0.004 (0.001) 0.004 (0.001)
INB CC 76.5 (43.7) 81.3 (41.6) 75.3 (43.5)
SL 117.0 (34.0) 117.4 (34.9) 117.9 (34.0)
SL-C 82.6 (33.8) 94.0 (32.4) 90.8 (33.3)
ML 82.7 (42.8) 82.5 (38.6) 82.6 (41.2)
ML-C 84.5 (38.0) 96.0 (38.2) 93.0 (38.5)
Figure 2. MI Estimates of mean (95%) incremental net benefit
(INB) from model ML-C (multilevel multiple imputation with in-
formative cluster size) versus model SL (ignoring clustering) using
bivariate Gamma-Normal substantive model
can and should be used, without the analyst having to modify the substantive
model.
12 K. DI´AZ-ORDAZ, M. KENWARD, AND R. GRIEVE
Our study highlights that a single-level imputation model can underestimate the
uncertainty surrounding the estimates of interest. More generally, Taljaard et al.
(2008) showed that MI approaches that ignore clustering can increase Type I errors.
Another common approach to handling missing data in CRTs is to include cluster
as a fixed effect in a single-level imputation model (White et al., 2011; Graham,
2009), but this does not produce an imputation model that properly captures the
conditional distribution of the missing data given the observed. Indeed, including
cluster as a fixed effect represents the limiting case where the ICC tends to one,
and does not reflect the variability of the imputed values. The simulation study
by Andridge (2011) found that including cluster as a fixed effect in the imputation
model, can overestimate the variance of the estimates, especially when ICCs are
low, and there are few clusters. Both features are common in our setting, a recent
review found that out of 63 published CEA alongside cluster trials, 40% had fewer
than 15 clusters per treatment arm, and one third reported ICCs of 0.01 or less for
health outcomes (Gomes et al., 2012b).
The case study presented here suggests that if there are cluster-level covariates
associated with the missingness patterns and the value of the outcomes to be im-
puted, then including them even in a single-level imputation model may potentially
provide more accurate point estimates. This is because including covariates that
predict dependency on cluster reduces the ICC. However, unless such covariates
fully explain the between-cluster variance, such single-level MI approaches would
still overstate precision. Hence, we propose imputation models with random effects
for clusters.
A general challenge in CEA is choosing appropriate statistical models for costs,
which tend to have right-skewed distributions. The bivariate models developed
here use marginal log-likelihoods for one outcome and conditional for the other, by
expressing the relationship between the two responses as a linear regression (see
sample code provided in Appendix A). In principle, these models are generalisable
to allow mixed distribution log-likelihoods, provided the conditional likelihood of
the dependent outcome is known explicitly and can be optimised. The advantage
of this approach is that, by parameterising the density according to the coefficient
of variation, and maximising the log-likelihood obtained, we avoid log-transforming
and re-transforming costs in the presence of heteroscedasticity (Manning, 1998;
Duan, 1983; Mullahy, 1998; Manning and Mullahy, 2001). We consider three cost
models that make alternative distributional assumptions, but keep an essentially
Lognormal imputation model throughout, and use standard optimisation routines
to obtain maximum likelihood estimates. Our findings suggest that assuming a
different distribution for the imputation versus analytical model appears to have
little impact, whereas the choice of whether or not the imputation model accounts
for clustering can be important.
A previous barrier to adopting principled MI approaches for hierarchical data
was the lack of available software, but this is no longer the case. There are now
three options for performing multilevel MI based on multivariate Normal MCMC
algorithms: PAN (Schafer and Yucel, 2002) which is available as an R package
(Development Core Team, 2011), the mi macro (Carpenter and Goldstein, 2004)
which operates within MLwiN (Rasbash et al., 2011) and can handle up to four
hierarchical levels and binary variables, and REALCOM-impute macros (Carpenter
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et al., 2011), which can also handle categorical variables and cluster-level variables
with missing data.
The approach presented in this paper has some limitations. For simplicity,
we assume the missing data mechanism is MAR throughout. However, MI pro-
vides a flexible and convenient route for investigating sensitivity to alternative
MNAR mechanisms (e.g. Carpenter et al., 2007), and in principle standard proce-
dures should apply without much modification. A further advantage of MI, which
this case study could not exploit, is that the imputation model may include post-
randomisation variables associated with missingness and endpoints, which should
not be included in the substantive model.
A further concern is that the imputation and analytical models may make incor-
rect distributional assumptions. Simulation studies by Schafer (1997) have shown
that MI can be fairly robust to model misspecification, but their simulation settings
did not include multilevel structures; Yucel and Dermitas (2010) recently investi-
gated the impact of misspecifing the multilevel imputation model but focused on
violations of the distributional assumptions for the random-effects. They find that
when the imputation model has sufficient auxiliary variables, inferences are insensi-
tive to non-Normal random-effects, unless the rates of missingness are very high or
the sample size is small. They obtained similar results when the assumption that
level-1 residuals were Normally distributed was violated.
While we propose a general approach to handling missing data in cluster trials,
it is illustrated through a single case study which cannot represent all the circum-
stances faced by CEA that use CRTs. There may be circumstances when the data
display quite different structures to those considered here, for example where there
are a high proportion with zero costs (Mullahy, 1998), QALYs with highly irreg-
ular distributions (Basu and Manca, 2012), or there are many auxiliary variables
available.
This paper suggests further extensions. Here, we combine multilevel MI with a
MLM estimated by maximum likelihood, but there may be circumstances where it
would be advantageous to combine multilevel MI with MLM estimated by Bayesian
MCMC (Lambert et al., 2005), for example when synthesising evidence across mul-
tiple sources (Welton et al., 2008); or indeed adopt a fully Bayesian approach to
handling the missingness and specifying the analytical models (Mason et al., 2012).
Future simulation studies could be useful in contrasting the relative performance
of the alternative approach across a broad range of settings including those where
there are a high proportion of observations with zero costs, health outcomes with
irregular distributions, and few clusters. Clearly, ignoring clustering in the impu-
tation model will have less impact as the ICC decreases. One way of reducing the
outstanding variation at the cluster-level within a single-level imputation model is
to introduce more cluster-level covariates. Further work is needed to assess under
what circumstances this simple MI approach would provide reliable inferences.
Finally, it would also be useful to extend the approaches to handling missing data
to other settings with hierarchical data. These could include trials with repeated
measures over time, studies with a high proportion of zero costs, censored costs, or
non-randomised studies where covariate adjustment is required.
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Appendix A. Implementation in SAS
We have developed a method that allows us to exploit the optimisation of general
likelihood functions available in SAS procedure NLMIXED. Briefly, we duplicated
the data and created an indicator variable for the first copy of the data, flag = 1.
We then used an if statement indicating we wished to estimate cost parameters if
flag = 1.
With this method, we were able to use marginal expressions of corresponding
log-likelihood to estimate parameters for costs using in turn either a Normal, Log-
normal or Gamma log-likelihood; the last two parameterised by the coefficient of
variation. We use Gauss-Hermite quadrature, with 70 quadrature points, and the
Newton-Raphson maximisation technique to estimate the maximum-likelihood pa-
rameters. As likelihood maximisation is sensitive to the initial parameters chosen
in the NLMIXED model, we ran this twice, using different initial values, to ensure
optimization had achieved convergence.
Sample SAS code can be found below.
proc nlmixed data=ponder2 method=Gauss qpoints=70 cov corr;
title "Control group bivariate Gamma-Normal with 2 Cluster Effects";
where group=0;
x=cost;
y=qalygain;
parms b0=268 c0=0.27 a=3 lsyx=-7 lnsc=8 lnse=2 r=0.01;
mux= b0+u1; varyx = exp(lsyx);
muyx= c0+u2+(varx*(a/mux**2))*x;
if (flag=1) then
ll=-x*a/mux+(a-1)*log(x)-a*log(mux)+a*log(a)-log(Gamma(a));
else ll=-(1/2)*log(2*constant(’pi’))-log(varyx)-((y-muyx)**2)/(2*varyx);
if (flag=1) then z = x;
else z = y;
model z ~ general(ll);
random u1 u2 ~ normal([0,0],[exp(lnsc),r, exp(lnse)]) subject=cluster;
estimate "my" c0+(varyx*(a/b0**2))*b0; run;
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